Treating Acute Covid-19 — Final Chapters Still Unwritten
Rajesh T. Gandhi, Martin Hirsch
Abstract
treatment with lixisenatide was statistically significant but small. The importance of this finding is not the magnitude of the change but what it portends. Indeed, the primary concern of most patients with Parkinson's disease is not their present condition -it is the fear of progression of the disease. If a three-point improvement in score on the MDS-UPDRS is the most that can be achieved with lixisenatide, then the value of treatment with the drug may be limited (especially in view of the adverse effects). On the other hand, if the benefit of lixisenatide is cumulative, adding another three points each year over a period of 5 to 10 years or more, then this could be a truly transformative treatment. The next step is clearly trials of longer duration to see whether GLP-1 receptor agonists can live up to Dr. Parkinson's prediction.